US 11,945,817 B2
Indolizine derivatives and their application in medicine
Dong Liu, Hangzhou (CN); Dongdong Chen, Hangzhou (CN); Biao Deng, Hangzhou (CN); Xiangyun Tu, Hangzhou (CN); Zinan Fang, Hangzhou (CN); Haohao Wu, Hangzhou (CN); and Danyan Gu, Hangzhou (CN)
Assigned to KIND PHARMACEUTICAL, Zhejiang (CN)
Filed by Kind Pharmaceutical, Hangzhou (CN)
Filed on Apr. 10, 2023, as Appl. No. 18/132,913.
Application 18/132,913 is a continuation of application No. 17/239,362, filed on Apr. 23, 2021, granted, now 11,655,249.
Application 17/239,362 is a continuation of application No. 16/611,838, granted, now 11,021,478, issued on Jun. 1, 2021, previously published as PCT/CN2018/086025, filed on May 8, 2018.
Claims priority of application No. 201710322377.2 (CN), filed on May 9, 2017.
Prior Publication US 2023/0257379 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61P 7/00 (2006.01); C07D 491/20 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 7/00 (2018.01); C07D 491/20 (2013.01)] 14 Claims
 
1. A compound of Formula I,

OG Complex Work Unit Chemistry
or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof,
in which
R1 and R2 are each independently selected from the group consisting of cyano, alkyl, heterocyclyl, alkenyl, alkynyl, aryl, heteroaryl, acyl, amino, R9O—, R9S—, R9(O═)S—, and R9(O═)2S—, wherein R9 is alkyl, heterocyclyl, alkenyl, alkynyl, aryl or heteroaryl; and wherein the alkyl, heterocyclyl, alkenyl, alkynyl, aryl, heteroaryl, acyl, and amino are optionally substituted by one or more substituents wherein the substituents are independently selected from the group consisting of halo, cyano, hydroxy, amino, carboxy, acyl, alkyl, heterocyclyl, alkenyl, alkynyl, aryl, heteroaryl, ═O, ═S, —SH, R10O—, R10S—,R10(O═)S—, and R10(O═)2S—, and wherein R10 is alkyl, heterocyclyl, alkenyl, alkynyl, aryl, or heteroaryl; or R1 and R2 are taken together to form a ring;
R3 is selected from the group consisting of alkyl, heterocyclyl, alkenyl, alkynyl, aryl, heteroaryl;
R6 and R6′ are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; and
R8 is selected from the group consisting of hydrogen, alkyl and —OC(O)R14, wherein R14 is alkyl, heterocyclyl, alkenyl, alkynyl, aryl or heteroaryl; wherein the alkyl, heterocyclyl, alkenyl, alkynyl, aryl, or heteroaryl group is optionally substituted with the following groups: halogen, cyano, hydroxy, amino, carboxy, acyl, alkyl, heterocyclyl, alkenyl, alkynyl, aryl, heteroaryl, ═O, ═S, —SH, R15O—, R15S—, R15(O═)S—, and/or R15(O═)2S—; wherein R15 is alkyl, heterocyclyl, alkenyl, alkynyl, aryl, or heteroaryl.